File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)

TitleA phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)
Authors
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2012
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 1-5 June 2012. In Journal of Clinical Oncology, 2012, v. 30 n. 15 suppl., abstract 4108 How to Cite?
AbstractBACKGROUND: Hepatocyte growth factor (HGF)/MET signalling plays a pivotal role in tumor cell proliferation, migration and invasion in HCC and circulating levels of HGF correlate with poor prognosis. This phase I/II trial (MET111645) evaluated foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR, as first-line therapy in …
DescriptionThis journal suppl. contain 2012 ASCO Meeting Abstracts
Open Access Journal
Persistent Identifierhttp://hdl.handle.net/10722/186976
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorYau, TCCen_US
dc.contributor.authorSukeepaisarnjaroen, Wen_US
dc.contributor.authorChao, Yen_US
dc.contributor.authorYen, CJen_US
dc.contributor.authorLausoontornsiri, Wen_US
dc.contributor.authorChen, PJen_US
dc.contributor.authorSanpajit, Ten_US
dc.contributor.authorLencioni, Ren_US
dc.contributor.authorCamp, ACen_US
dc.contributor.authorCox, DSen_US
dc.contributor.authorKallender, Hen_US
dc.contributor.authorOttesen, LHen_US
dc.contributor.authorPoon, RTPen_US
dc.date.accessioned2013-08-20T12:26:30Z-
dc.date.available2013-08-20T12:26:30Z-
dc.date.issued2012en_US
dc.identifier.citationThe 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 1-5 June 2012. In Journal of Clinical Oncology, 2012, v. 30 n. 15 suppl., abstract 4108en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/186976-
dc.descriptionThis journal suppl. contain 2012 ASCO Meeting Abstracts-
dc.descriptionOpen Access Journal-
dc.description.abstractBACKGROUND: Hepatocyte growth factor (HGF)/MET signalling plays a pivotal role in tumor cell proliferation, migration and invasion in HCC and circulating levels of HGF correlate with poor prognosis. This phase I/II trial (MET111645) evaluated foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR, as first-line therapy in …-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleA phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)en_US
dc.typeConference_Paperen_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros217114en_US
dc.identifier.volume30en_US
dc.identifier.issue15 suppl.en_US
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 131010-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats